Chronic Lymphocytic Leukemia | Specialty

Dr. Wierda on Combination Regimens With Venetoclax in CLL

December 4th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Novel Agents Increasingly Individualize CLL Care

November 24th 2015

William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.

Novel Agents Offer Promise in CLL, But Challenges Remain

November 17th 2015

Dr. Thomas Kipps discusses how challenges in CLL may be met in the future and the impact obinutuzumab, venetoclax, and other novel agents could have on CLL treatment.

Positive Interim Analysis Halts Phase III Idelalisib CLL Study

November 16th 2015

A phase III study exploring idelalisib in combination with bendamustine and rituximab for patients with previously treated chronic lymphocytic leukemia has been stopped early following a positive interim analysis.

Label Update Sought for Ibrutinib in CLL

November 13th 2015

A supplemental new drug application has been submitted for ibrutinib (Imbruvica) for use in combination with bendamustine and rituximab to treat patients with relapsed or refractory chronic lymphocytic leukemia.

New Blood Cancer Landscape Taking Shape

November 12th 2015

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

B-cell Pathway Inhibitors Show Clear Benefit in CLL

November 4th 2015

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

Anti-CD20 Antibodies Effective in Elderly CLL Patients

October 27th 2015

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

Potential Driver Mutations Identified in CLL

October 27th 2015

Dozens of genetic abnormalities, including 44 mutated genes and 11 recurrent somatic copy number variations, were found to potentially play a role in progression and/or relapse of chronic lymphocytic leukemia.

Dr. Ferrajoli on Treatment of Elderly Patients With CLL

October 22nd 2015

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Emerging Treatments for Chronic Lymphocytic Leukemia

October 20th 2015

Utilizing Maintenance Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Therapeutic Combinations and Sequences for CLL

October 20th 2015

Using BCR-Targeted Agents for Relapsed/Refractory CLL

October 20th 2015

Anti-CD20 Antibodies for Chronic Lymphocytic Leukemia

October 20th 2015

Ongoing Role of Transplant in Chronic Lymphocytic Leukemia

October 20th 2015

Minimal Residual Disease in Chronic Lymphocytic Leukemia

October 20th 2015

Treating Younger and Older Patients With CLL

October 20th 2015

Initiating Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.